Seelos Therapeutics, Inc. (SEEL): Price and Financial Metrics
GET POWR RATINGS... FREE!
SEEL Stock Price Chart Interactive Chart >
SEEL Price/Volume Stats
|Current price||$2.35||52-week high||$6.60|
|Prev. close||$2.27||52-week low||$0.72|
|Day high||$2.37||Avg. volume||5,794,422|
|50-day MA||$2.15||Dividend yield||N/A|
|200-day MA||$3.15||Market Cap||240.44M|
Seelos Therapeutics, Inc. (SEEL) Company Bio
Seelos Therapeutics, Inc. operates as a biotechnology company. The Company develops treatments for post-traumatic stress and major depressive disorders. Seelos Therapeutics serves patients in the United States.
Most Popular Stories View All
SEEL Latest News Stream
|Loading, please wait...|
SEEL Latest Social Stream
View Full SEEL Social Stream
Latest SEEL News From Around the Web
Below are the latest news stories about Seelos Therapeutics Inc that investors may wish to consider to help them evaluate SEEL as an investment opportunity.
Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster on SLS-002 (Intranasal Racemic Ketamine) at the IASR/AFSP International Summit on Suicide Research Virtual Conference, October 24-27th, 2021.
Part A results from the trial of Seelos Therapeutics Incs (NASDAQ: SEEL ) intranasal ketamine product candidate, SLS-002, and the
Seelos Therapeutics Inc (NASDAQ:SEEl) is trading higher Monday after Roth Capital analyst Jonathan Aschoff upgraded the stock from Neutral to Buy and raised the price target from $2.50 to $8. The Roth Capital analyst said the firm's optimism has increased, citing "the stock having found far firmer ground and the transience of the increase in CADSS." Three encouraging features of the ongoing SLS-002 trial came from observing faults with the Spravato trials, Aschoff said: "Requirement for suicidal
Investors need to pay close attention to Seelos (SEEL) stock based on the movements in the options market lately.
The Sean M. Healey & AMG Center for ALS at Mass General received approval from the FDA and the Mass General Brigham Institutional Review Board to add SLS-005 (trehalose injection, 90.5 mg/ML for intravenous infusion) as an additional regimen in the HEALEY ALS Platform Trial. HEALEY ALS Trial Design Committee worked with Seelos Therapeutics Inc (NASDAQ: SEEL) to include SLS-005’s pivotal Phase 2b/3 trial in amyotrophic lateral sclerosis (ALS) on the platform. The drug received Orphan Drug Designa
SEEL Price Returns